Position in ALKS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,505,744
+$2,610,145 QoQ
Shares Held
183,986
+32.1% QoQ
Ownership
0.110%
of shares outstanding
% of Portfolio
0.38%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Rock Springs Capital Management LP holds $43,551,047 across 7 Drug Manufacturers - Specialty & Generic names. ALKS ranks #3 (14.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
150,450 | $19,820,283 | |
| 2 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
499,764 | $6,946,719 | |
| 3 | ALKS |
Alkermes plc.
This page
|
183,986 | $6,505,744 | |
| 4 | INDV |
Indivior Pharmaceuticals, Inc.
|
200,000 | $6,096,000 | |
| 5 | TLPH |
Talphera, Inc.
|
3,589,186 | $2,691,889 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
45,500 | $1,370,460 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
12,600 | $119,952 |
All Filings in ALKS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,505,744 | 183,986 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,895,599 | 139,228 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,196,110 | 106,537 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||